GlycoMimetics (NASDAQ: GLYC) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap bio therapeutic drugs companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for GlycoMimetics and Redhill Biopharma, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GlycoMimetics 0 0 6 0 3.00
Redhill Biopharma 0 0 4 0 3.00

GlycoMimetics currently has a consensus target price of $18.20, indicating a potential upside of 48.33%. Redhill Biopharma has a consensus target price of $25.00, indicating a potential upside of 381.70%. Given Redhill Biopharma’s higher probable upside, analysts plainly believe Redhill Biopharma is more favorable than GlycoMimetics.

Volatility & Risk

GlycoMimetics has a beta of 3.14, meaning that its share price is 214% more volatile than the S&P 500. Comparatively, Redhill Biopharma has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Insider and Institutional Ownership

92.5% of GlycoMimetics shares are held by institutional investors. Comparatively, 10.7% of Redhill Biopharma shares are held by institutional investors. 43.8% of GlycoMimetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares GlycoMimetics and Redhill Biopharma’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
GlycoMimetics $20,000.00 21,067.59 -$31.80 million ($1.24) -9.90
Redhill Biopharma $100,000.00 1,103.91 -$29.37 million N/A N/A

Redhill Biopharma has higher revenue and earnings than GlycoMimetics.

Profitability

This table compares GlycoMimetics and Redhill Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
GlycoMimetics N/A -28.47% -26.86%
Redhill Biopharma N/A -76.53% -63.38%

Summary

GlycoMimetics beats Redhill Biopharma on 7 of the 10 factors compared between the two stocks.

About GlycoMimetics

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.

About Redhill Biopharma

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn’s disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103).

Receive News & Ratings for GlycoMimetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.